^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CD33 expression

    i
    Other names: CD33, CD33 Molecule, Sialic Acid-Binding Ig-Like Lectin 3, Myeloid Cell Surface Antigen CD33, CD33 Antigen (Gp67), SIGLEC3, Gp67, Sialic Acid Binding Ig-Like Lectin 3, CD33 Molecule Transcript, CD33 Antigen, SIGLEC-3, Siglec-3, P67
    Entrez ID:
    945
    Related biomarkers:
    Expression
    11ms
    NCI-2018-01613: Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia (clinicaltrials.gov)
    P2, N=36, Recruiting, University of Washington | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    CD33 (CD33 Molecule)
    |
    CD33 expression
    |
    Mylotarg (gemtuzumab ozogamicin)
    11ms
    c-JUN interacts with HDAC1 as a potential combinatorial therapeutic target in acute myeloid leukemia. (PubMed, Int Immunopharmacol)
    The combination of agents targeting c-JUN (Ailanthone) and HDAC1 (Panobinostat) showed robust efficacy in treating AML in xenograft mouse models, outperforming monotherapy. We also observed that the combination of Ailanthone and Panobinostat therapy displayed a safe pharmacological profile without dose-dependent toxicity, suggesting its potential as a therapeutic strategy.
    Journal
    |
    CD33 (CD33 Molecule) • HDAC1 (Histone Deacetylase 1) • JUN (Jun proto-oncogene)
    |
    CD33 expression
    |
    Farydak (panobinostat)
    12ms
    NCI-2019-01726: Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, Uma Borate | Recruiting --> Active, not recruiting | Trial completion date: Jan 2025 --> Dec 2025 | Trial primary completion date: Jan 2025 --> Jun 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    FLT3 (Fms-related tyrosine kinase 3) • CD33 (CD33 Molecule)
    |
    CD33 positive • CD33 expression
    |
    cytarabine • midostaurin • Mylotarg (gemtuzumab ozogamicin) • daunorubicin • Starasid (cytarabine ocfosfate)
    1year
    Clinical analysis of 7 cases of acute B cell lymphoblastic leukemia with t (17;19) (q21-22;p13)/TCF3-HLF fusion (PubMed, Zhonghua Xue Ye Xue Za Zhi)
    Two patients did not achieve remission even after two rounds of induction chemotherapy, with one achieving complete remission after treatment with blinatumomab immunotherapy...Five patients died, while two patients survived with sustained complete remission. TCF3-HLF-positive B-ALL is rare and has a high relapse rate and poor prognosis.
    Retrospective data • Journal • IO biomarker
    |
    CD33 (CD33 Molecule) • TCF3 (Transcription Factor 3)
    |
    CD33 positive • CD33 expression
    |
    Blincyto (blinatumomab)
    over1year
    Targeting the membrane-proximal C2-set domain of CD33 for improved CAR T cell therapy. (PubMed, Mol Ther Oncol)
    CD33PAN moieties were detected at a higher frequency on human leukemic stem cells, and CD33PAN CAR T cells had greater in vitro efficacy against primary human AML cells. Together, our studies demonstrate improved efficacy with CAR T cells binding CD33 close to the cell membrane, providing the rationale to investigate CD33PAN CAR T cells further toward possible clinical application.
    Journal • CAR T-Cell Therapy • IO biomarker
    |
    CD33 (CD33 Molecule)
    |
    CD33 expression
    |
    CD33PAN CAR T
    over1year
    NCI-2019-01726: Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=18, Suspended, Uma Borate | Recruiting --> Suspended
    Trial suspension
    |
    FLT3 (Fms-related tyrosine kinase 3) • CD33 (CD33 Molecule)
    |
    CD33 positive • CD33 expression
    |
    cytarabine • midostaurin • Mylotarg (gemtuzumab ozogamicin) • daunorubicin • Starasid (cytarabine ocfosfate)
    over1year
    Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1/2, N=52, Recruiting, Center for International Blood and Marrow Transplant Research | Active, not recruiting --> Recruiting | Trial primary completion date: Dec 2024 --> Dec 2029
    Enrollment open • Trial primary completion date
    |
    CD33 expression
    |
    cyclophosphamide
    over1year
    Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy (clinicaltrials.gov)
    P2, N=16, Active, not recruiting, Robert Redner, MD | Completed --> Active, not recruiting | Trial completion date: Feb 2023 --> Dec 2028
    Enrollment closed • Trial completion date
    |
    CD33 (CD33 Molecule)
    |
    CD33 expression
    |
    etoposide IV • Mylotarg (gemtuzumab ozogamicin) • mitoxantrone
    almost2years
    NCI-2019-01726: Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=18, Recruiting, Uma Borate | Trial primary completion date: Jan 2024 --> Jan 2025
    Trial primary completion date • Combination therapy
    |
    FLT3 (Fms-related tyrosine kinase 3) • CD33 (CD33 Molecule)
    |
    CD33 positive • CD33 expression
    |
    cytarabine • midostaurin • Mylotarg (gemtuzumab ozogamicin) • daunorubicin • Starasid (cytarabine ocfosfate)
    almost2years
    VBP101: Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML (clinicaltrials.gov)
    P1/2, N=24, Recruiting, Vor Biopharma | N=18 --> 24 | Trial completion date: Sep 2025 --> Jan 2027 | Trial primary completion date: Dec 2023 --> Feb 2025
    Enrollment change • Trial completion date • Trial primary completion date
    |
    CD33 (CD33 Molecule) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    CD33 expression
    |
    Mylotarg (gemtuzumab ozogamicin) • tremtelectogene empogeditemcel (VOR33)
    almost2years
    Dual-targeting CD33/CD123 NANOBODY® T cell engager with potent anti-AML activity and good safety profile. (PubMed, Blood Adv)
    Depletion of CD123 and CD33 expressing cells was observed, without signs of cytokine release syndrome nor clinical signs of toxicity. Taken together, the CD33/CD123 dual-targeting NANOBODY® TCE exhibits potent and safe anti-AML activity and promises a broad patient coverage.
    Journal
    |
    CD123 (Interleukin 3 Receptor Subunit Alpha) • CD33 (CD33 Molecule) • IL3RA (Interleukin 3 Receptor Subunit Alpha)
    |
    CD33 expression • CD123 expression • IL3RA expression
    almost2years
    Gemtuzumab ozogamicin for relapsed or primary refractory acute myeloid leukemia in children-the Polish Pediatric Leukemia and Lymphoma Study Group experience. (PubMed, Front Immunol)
    Sinusoidal obstruction syndrome occurred in two children. The use of GO in severely pretreated children, including those under 15 years of age, with previous failure of AML treatment is a feasible and effective bridging therapy to allo-HSCT with an acceptable toxicity profile.
    Retrospective data • Journal
    |
    CD33 (CD33 Molecule)
    |
    CD33 expression
    |
    Mylotarg (gemtuzumab ozogamicin)